Forte Biosciences vs Bio-Thera Solutions: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Forte Biosciences Inc (FBRX)

Q3 202623 Jul – 29 Jul 2026

▲3

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

July 202623 Jul – 29 Jul 2026

▲3

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

Latest23 Jul – 29 Jul 2026

▲3

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.